{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:44:22Z","timestamp":1794008662478,"version":"4.8.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1038\/s41591-025-04121-8","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:05:51Z","timestamp":1768471551000},"page":"702-716","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7937-1557","authenticated-orcid":false,"given":"Matthew","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6505-0194","authenticated-orcid":false,"given":"Luca","family":"Paruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-7378","authenticated-orcid":false,"given":"Julia Han","family":"Noll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3401-1309","authenticated-orcid":false,"given":"Federico","family":"Stella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Ndeupen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael A.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3265-6878","authenticated-orcid":false,"given":"Angel","family":"Ramirez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Kapur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-3887","authenticated-orcid":false,"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8571-3218","authenticated-orcid":false,"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Jarocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrutti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2858-9986","authenticated-orcid":false,"given":"Audrey C.","family":"Bochi-Layec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjani","family":"Ramasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riemke","family":"Bouvier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2370-9856","authenticated-orcid":false,"given":"Vitor B.","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heta","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Carturan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Michener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin R.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Koucky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8053-690X","authenticated-orcid":false,"given":"Janna","family":"Minehart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Dimitri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel R.","family":"Nabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9150-089X","authenticated-orcid":false,"given":"Zainul S.","family":"Hasanali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan T.","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Putzer","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bartoszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Lavorando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4025-115X","authenticated-orcid":false,"given":"Suyash","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa E.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Porazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay G.","family":"Bhoj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0224-0097","authenticated-orcid":false,"given":"Sokratis A.","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2935-2566","authenticated-orcid":false,"given":"Dan T.","family":"Vogl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Scholler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-3836","authenticated-orcid":false,"given":"Caroline","family":"Diorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife M.","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John K.","family":"Everett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-4056","authenticated-orcid":false,"given":"Frederic D.","family":"Bushman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Nathanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Stadtmauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0703-2518","authenticated-orcid":false,"given":"Sandra P.","family":"Susanibar-Adaniya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-5748","authenticated-orcid":false,"given":"Alfred L.","family":"Garfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7900-8993","authenticated-orcid":false,"given":"Joseph A.","family":"Fraietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"4121_CR1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"4121_CR2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4121_CR3","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4121_CR4","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen, D. K. et al. Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium. J. Clin. Oncol. 41, 2087\u20132097 (2023).","journal-title":"J. Clin. Oncol."},{"key":"4121_CR5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"4121_CR6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4121_CR7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana, S. et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood 145, 85\u201397 (2025).","journal-title":"Blood"},{"key":"4121_CR8","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1080\/03007995.2024.2391112","volume":"40","author":"N Bar","year":"2024","unstructured":"Bar, N. et al. Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2\u22124 prior lines of therapy: a matching-adjusted indirect comparison. Curr. Med. Res. Opin. 40, 1597\u20131603 (2024).","journal-title":"Curr. Med. Res. Opin."},{"key":"4121_CR9","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2024-202676","volume":"144","author":"O Nadeem","year":"2024","unstructured":"Nadeem, O. et al. Early safety and efficacy of CAR-T cell therapy in precursor myeloma: results of the CAR-PRISM study using ciltacabtagene autoleucel in high-risk smoldering myeloma. Blood 144, 1027 (2024).","journal-title":"Blood"},{"key":"4121_CR10","unstructured":"Wenqiang Yan, C. D. et al. BCMA CAR-T therapy as first-line consolidation treatment in transplant-ineligible patients with newly-diagnosed multiple myeloma: an open label, single-arm, phase 2 study (CAREMM-001). https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper199913.html (American Society of Hematology, 2024)."},{"key":"4121_CR11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","volume":"4","author":"AL Garfall","year":"2023","unstructured":"Garfall, A. L. et al. Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discov. 4, 118\u2013133 (2023).","journal-title":"Blood Cancer Discov."},{"key":"4121_CR12","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1182\/blood-2022-157021","volume":"140","author":"M Boccadoro","year":"2022","unstructured":"Boccadoro, M. et al. DVRd followed by ciltacabtagene autoleucel versus DVRd followed by ASCT in patients with newly diagnosed multiple myeloma who are transplant eligible: a randomized phase 3 study (EMagine\/CARTITUDE-6). Blood 140, 4630\u20134632 (2022).","journal-title":"Blood"},{"key":"4121_CR13","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski, K. et al. Immune effector cell\u2013associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142, 865\u2013877 (2023).","journal-title":"Blood"},{"key":"4121_CR14","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines, M. R. et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant. Cell. Ther. 29, 438.e1\u2013438.e16 (2023).","journal-title":"Transplant. Cell. Ther."},{"key":"4121_CR15","doi-asserted-by":"crossref","first-page":"71.e1","DOI":"10.1016\/j.jtct.2024.12.002","volume":"31","author":"M Ellithi","year":"2025","unstructured":"Ellithi, M. et al. Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data. Transplant. Cell. Ther. 31, 71.e1\u201371.e14 (2025).","journal-title":"Transplant. Cell. Ther."},{"key":"4121_CR16","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen, O. et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat. Med. 27, 2099\u20132103 (2021).","journal-title":"Nat. Med."},{"key":"4121_CR17","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen, A. D. et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 12, 32 (2022).","journal-title":"Blood Cancer J."},{"key":"4121_CR18","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna, G. G. et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 14, 180 (2024).","journal-title":"Blood Cancer J."},{"key":"4121_CR19","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin, Q. et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front. Immunol. 14, 1167975 (2023).","journal-title":"Front. Immunol."},{"key":"4121_CR20","doi-asserted-by":"crossref","first-page":"E241","DOI":"10.1002\/ajh.26561","volume":"97","author":"R Bansal","year":"2022","unstructured":"Bansal, R. et al. Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. Am. J. Hematol. 97, E241\u2013E244 (2022).","journal-title":"Am. J. Hematol."},{"key":"4121_CR21","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou, X. et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 18, 87 (2020).","journal-title":"BMC Med."},{"key":"4121_CR22","unstructured":"Jadlowsky, J. K. et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat. Med. 31, 1134\u22121144 (2025)."},{"key":"4121_CR23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/eji.200425577","volume":"35","author":"JP Chen","year":"2005","unstructured":"Chen, J. P. et al. Reduced 2,4-dinitro-1-fluorobenzene-induced contact hypersensitivity response in IL-15 receptor \u03b1-deficient mice correlates with diminished CCL5\/RANTES and CXCL10\/IP-10 expression. Eur. J. Immunol. 35, 690\u2013698 (2005).","journal-title":"Eur. J. Immunol."},{"key":"4121_CR24","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2567.2010.03252.x","volume":"130","author":"M Gil","year":"2010","unstructured":"Gil, M., Park, S. J., Chung, Y. S. & Park, C. S. Interleukin-15 enhances proliferation and chemokine secretion of human follicular dendritic cells. Immunology 130, 536\u2013544 (2010).","journal-title":"Immunology"},{"key":"4121_CR25","volume":"613","author":"P Jin","year":"2025","unstructured":"Jin, P. et al. Synergistic enhancement of radio-immunotherapy efficacy by IL-15 via macrophage activation and memory T cell response. Cancer Lett. 613, 217511 (2025).","journal-title":"Cancer Lett."},{"key":"4121_CR26","doi-asserted-by":"crossref","unstructured":"Li, Y., Gao, H., Clark, K. M. & Shan, L. IL-15 enhances HIV-1 infection by promoting survival and proliferation of CCR5+CD4+ T cells. JCI Insight 8, e166292 (2023).","DOI":"10.1172\/jci.insight.166292"},{"key":"4121_CR27","unstructured":"Schechter, J. M. & Fan, X. BCMA-targeted CAR-T-cell therapy for multiple myeloma. World Intellectual Property Organization patent no. WO2023164695A2 (2023)."},{"key":"4121_CR28","unstructured":"Campbell, T. et al. Uses of anti-BCMA chimeric antigen receptors. World Intellectual Property Organization patent no. PCT\/US2020\/058835 (2021)."},{"key":"4121_CR29","doi-asserted-by":"crossref","first-page":"17608","DOI":"10.18632\/oncotarget.24807","volume":"9","author":"S Rosskopf","year":"2018","unstructured":"Rosskopf, S. et al. A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies. Oncotarget 9, 17608\u201317619 (2018).","journal-title":"Oncotarget"},{"key":"4121_CR30","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-60980-2","volume":"16","author":"D Atanackovic","year":"2025","unstructured":"Atanackovic, D. et al. Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma. Nat. Commun. 16, 6154 (2025).","journal-title":"Nat. Commun."},{"key":"4121_CR31","volume":"407","author":"FF Qu","year":"2025","unstructured":"Qu, F. F. et al. The CCL5\/CCR5 axis in ulcerative colitis. Cell. Immunol. 407, 104891 (2025).","journal-title":"Cell. Immunol."},{"key":"4121_CR32","doi-asserted-by":"crossref","first-page":"155640","DOI":"10.1016\/j.cyto.2021.155640","volume":"146","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard, S., Shahir, M., Taheri, M. & Salimi, A. A review on the role of chemokines in the pathogenesis of systemic lupus erythematosus. Cytokine 146, 155640 (2021).","journal-title":"Cytokine"},{"key":"4121_CR33","first-page":"1930","volume":"24","author":"H Koski","year":"1997","unstructured":"Koski, H., Konttinen, Y. T., Hietanen, J., Tervo, T. & Malmstr\u00f6m, M. Epidermal growth factor, transforming growth factor-alpha, and epidermal growth factor receptor in labial salivary glands in Sj\u00f6gren\u2019s syndrome. J. Rheumatol. 24, 1930\u20131935 (1997).","journal-title":"J. Rheumatol."},{"key":"4121_CR34","doi-asserted-by":"crossref","unstructured":"Murayama, M. A., Shimizu, J., Miyabe, C., Yudo, K. & Miyabe, Y. Chemokines and chemokine receptors as promising targets in rheumatoid arthritis. Front. Immunol. 14, 1100869 (2023).","DOI":"10.3389\/fimmu.2023.1100869"},{"key":"4121_CR35","doi-asserted-by":"crossref","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","volume":"7","author":"S Cook","year":"2024","unstructured":"Cook, S. et al. Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw. Open 7, e2352302 (2024).","journal-title":"JAMA Netw. Open"},{"key":"4121_CR36","doi-asserted-by":"crossref","unstructured":"Sullivan, R. J. et al. SITC vision: opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy. J. Immunother. Cancer 13, e011929 (2025).","DOI":"10.1136\/jitc-2025-011929"},{"key":"4121_CR37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh, D. et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol. Res. 7, 759\u2013772 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"4121_CR38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/bloodadvances.2023011492","volume":"8","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines. Blood Adv. 8, 653\u2013666 (2024).","journal-title":"Blood Adv."},{"key":"4121_CR39","doi-asserted-by":"crossref","unstructured":"Tian, G. et al. Hyperleukocytosis in a neuroblastoma patient after treatment with natural killer T cells expressing a GD2-specific chimeric antigen receptor and IL-15. J. Immunother. Cancer 13, e010156 (2025).","DOI":"10.1136\/jitc-2024-010156"},{"key":"4121_CR40","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1038\/s41409-020-0888-3","volume":"55","author":"P Khandelwal","year":"2020","unstructured":"Khandelwal, P. et al. CCR5 inhibitor as novel acute graft versus host disease prophylaxis in children and young adults undergoing allogeneic stem cell transplant: results of the phase II study. Bone Marrow Transplant. 55, 1552\u20131559 (2020).","journal-title":"Bone Marrow Transplant."},{"key":"4121_CR41","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.bbmt.2018.09.034","volume":"25","author":"R Reshef","year":"2019","unstructured":"Reshef, R. et al. Extended CCR5 blockade for graft-versus-host disease prophylaxis improves outcomes of reduced-intensity unrelated donor hematopoietic cell transplantation: a phase II clinical trial. Biol. Blood Marrow Transplant. 25, 515\u2013521 (2019).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"4121_CR42","doi-asserted-by":"crossref","first-page":"S202","DOI":"10.1016\/j.jtct.2025.01.313","volume":"31","author":"KJC Lim","year":"2025","unstructured":"Lim, K. J. C. et al. Risk factors for delayed neurotoxicity in patients with relapsed myeloma who received ciltacabtagene autoleucel (cilta-cel). Transplant. Cell. Ther. 31, S202 (2025).","journal-title":"Transplant. Cell. Ther."},{"key":"4121_CR43","doi-asserted-by":"crossref","unstructured":"Pinto, S. N. & Krenciute, G. The mechanisms of altered blood\u2212brain barrier permeability in CD19 CAR T-cell recipients. Int. J. Mol. Sci. 25, 644 (2024).","DOI":"10.3390\/ijms25010644"},{"key":"4121_CR44","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.ymthe.2023.06.006","volume":"31","author":"AR Haas","year":"2023","unstructured":"Haas, A. R. et al. Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells. Mol. Ther. 31, 2309\u20132325 (2023).","journal-title":"Mol. Ther."},{"key":"4121_CR45","volume":"4","author":"M Boulch","year":"2023","unstructured":"Boulch, M. et al. A major role for CD4+ T cells in driving cytokine release syndrome during CAR T cell therapy. Cell Rep. Med. 4, 101161 (2023).","journal-title":"Cell Rep. Med."},{"key":"4121_CR46","volume":"13","author":"CA James","year":"2022","unstructured":"James, C. A. et al. CD4 and CD8 co-receptors modulate functional avidity of CD1b-restricted T cells. Nat. Commun. 13, 78 (2022).","journal-title":"Nat. Commun."},{"key":"4121_CR47","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.4049\/jimmunol.1500400","volume":"195","author":"SY Lee","year":"2015","unstructured":"Lee, S. Y. et al. IL-12p40 homodimer ameliorates experimental autoimmune arthritis. J. Immunol. 195, 3001\u20133010 (2015).","journal-title":"J. Immunol."},{"key":"4121_CR48","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/mi.2016.135","volume":"10","author":"E Marks","year":"2017","unstructured":"Marks, E. et al. Regulation of IL-12p40 by HIF controls Th1\/Th17 responses to prevent mucosal inflammation. Mucosal Immunol. 10, 1224\u20131236 (2017).","journal-title":"Mucosal Immunol."},{"key":"4121_CR49","doi-asserted-by":"crossref","first-page":"21557","DOI":"10.1073\/pnas.2000653117","volume":"117","author":"S Mondal","year":"2020","unstructured":"Mondal, S. et al. IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12R\u03b21 internalization and suppress EAE. Proc. Natl Acad. Sci. USA 117, 21557\u201321567 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"4121_CR50","doi-asserted-by":"crossref","unstructured":"Turner, J. et al. Prophylactic dexamethasone rescues unrestrained lymphocyte expansion in anti-BCMA chimeric antigen receptor T cell therapy in multiple myeloma. Transplant. Cell. Ther. 31, S215\u2212S216 (2025).","DOI":"10.1016\/j.jtct.2025.01.330"},{"key":"4121_CR51","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01048-0","volume":"14","author":"BA Costa","year":"2024","unstructured":"Costa, B. A. et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 14, 84 (2024).","journal-title":"Blood Cancer J."},{"key":"4121_CR52","unstructured":"mSMART. Stratification for Myeloma and Risk-Adapted Therapy. https:\/\/www.msmart.org\/"},{"key":"4121_CR53","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41375-021-01433-9","volume":"36","author":"S Zanwar","year":"2022","unstructured":"Zanwar, S. et al. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia 36, 873\u2013876 (2022).","journal-title":"Leukemia"},{"key":"4121_CR54","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"4121_CR55","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073\u20134126 (2021).","journal-title":"J. Clin. Oncol."},{"key":"4121_CR56","unstructured":"Huwaldt, J. A. PlotDigitizer. https:\/\/sourceforge.net\/projects\/plotdigitizer\/ (2016)."},{"key":"4121_CR57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.omtm.2016.11.002","volume":"4","author":"E Sherman","year":"2017","unstructured":"Sherman, E. et al. INSPIIRED: a pipeline for quantitative analysis of sites of new DNA integration in cellular genomes. Mol. Ther. Methods Clin. Dev. 4, 39\u201349 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"4121_CR58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.omtm.2016.11.003","volume":"4","author":"CC Berry","year":"2017","unstructured":"Berry, C. C. et al. INSPIIRED: quantification and visualization tools for analyzing integration site distributions. Mol. Ther. Methods Clin. Dev. 4, 17\u201326 (2017).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"4121_CR59","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1172\/JCI130144","volume":"130","author":"CL Nobles","year":"2020","unstructured":"Nobles, C. L. et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J. Clin. Invest. 130, 673\u2013685 (2020).","journal-title":"J. Clin. Invest."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04121-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T18:03:13Z","timestamp":1771783393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-04121-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4121"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-04121-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.T.V. has received research funding from Takeda and Active Biotech and consulting fees from Takeda, Karyopharm, GlaxoSmithKline, Genentech and Sanofi. A.D.C. has received research support from Novartis, GlaxoSmithKline, Genentech and Janssen; consulting fees from Janssen, Bristol Myers Squibb, GlaxoSmithKline, Genentech, Legend, Sanofi, Pfizer, AbbVie, Regeneron, Moderna, AstraZeneca, iTeos, Prothena, Kite, Novartis and Ichnos; and has patents related to CAR T cells. A.L.G. declares research support from Johnson & Johnson, Novartis, Tmunity and CRISPR Therapeutics; consultancies\/honoraria from Johnson & Johnson, Novartis, Bristol Myers Squibb, Regeneron, AbbVie, AstraZeneca, Smart Immune and Gracell Bio; and data and safety monitoring board membership for Johnson & Johnson. E.A.S. declares an affiliation with Oncopeptides and consultancy for Amgen, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen and AbbVie. J.A.F. has patents and intellectual property in T-cell-based cancer immunotherapy with royalties; funding from Tmunity Therapeutics and Danaher Corporation; consultancy with Retro Biosciences; and scientific advisory board membership with Cartography Bio, Shennon Biotechnologies, CellFe Biotech, OverT Bio and Tceleron Therapeutics. D.L.P declares research funding from Novartis and Bristol Myers Squibb, membership on an entity\u2019s board of directors (National Marrow Donor Program) and advisory committee or honoraria from Novartis, Kite\/Gilead, Angiocrine, Mirror Biologics, Sana Biotechnology and Verismo. D.L.P. is a current equity holder in Genentech and has patents and royalties with Novartis and Tmunity\/Kite. C.D. declares consultancy with Merck. V.B. declares consulting fees from Alexion and has patents related to CAR T cell platforms for treatment of alloimmune conditions and autoimmune diseases. S.M. has received research funding from Novocure and Galileo CDS and is an advisory board member for Servier Pharmaceuticals and Guerbet. F.D.B. has engaged with Sana Biotechnology. S.P.S.-A. declares consultancies\/honoraria from Johnson & Johnson. M.R. has patents related to CD19 CAR T cells; consults for GLG, Guidepoint, AbClon, Acera and Vittoria Bio; received research funding from AbClon, Oxford NanoImaging, Vittoria Biotherapeutics, CURIOX and Beckman Coulter; and is the scientific founder of Vittoria Biotherapeutics. M.H., L.P., J.H.N., A.L.G., M.R., A.D.C. and J.A.F. have filed patent applications related to this work. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}